The revenue decline and cash burn confirm the company remains pre-profitability and dependent on capital markets. The inFoods Medicare reimbursement progress and CDMO deal are positive catalysts, but the dilutive raise and low cash position ($1.3M pre-raise) suggest high risk of further dilution.
Price Chart
Executive Summary
Biomerica reported fiscal 2026 Q4 net sales of ~$875K (+17% YoY) and a net loss improvement to ~$1.1M, while full-year revenue fell 15% to $4.5M. The company highlighted progress on inFoods IBS Medicare reimbursement (100% of valid claims paid at $300 CMS rate), a $1.75M CDMO agreement, and a $2.23M dilutive private placement post-year-end.
Key Financial Metrics
Key Facts
- Q4 fiscal 2026 net sales ~$875K, up ~17% YoY from ~$749K.
- Full-year fiscal 2026 revenue $4.50M, down ~15% from $5.30M in fiscal 2025.
- Full-year net loss improved ~24% to ~$3.8M from ~$5.0M; net loss per share $(1.30) vs $(2.16).
- Cash and cash equivalents $1.3M at May 31, 2026, down from $2.4M a year earlier.
- Post-year-end private placement raised ~$2.23M from 1.39M shares at $1.60/share, including B. Riley and all board members.
- inFoods IBS Medicare claims: 100% of initial valid claims paid at full CMS rate of $300.
- Entered $1.75M CDMO agreement with a confidential life sciences company for IVD assay development.
- First commercial order for hp+detect received from a major European lab chain.
- Engaged B. Riley Securities to evaluate strategic opportunities including partnerships and M&A.
Financial Impact
Full-year revenue declined ~$0.8M (15% YoY) to $4.5M; net loss improved ~$1.2M to $3.8M; cash burn $3.4M; post-year-end $2.23M dilutive raise provides ~6-8 months of runway at current burn rate.
Risk Factors
- Full-year revenue decline of 15% signals core business contraction despite inFoods growth.
- Cash burn of $3.4M vs $1.3M year-end cash (pre-raise) shows acute capital needs; $2.23M raise provides limited runway.
- Dilutive private placement at $1.60/share (near current price) adds ~1.4M shares to a ~$9M market cap.
- Reliance on Medicare reimbursement expansion for inFoods is unproven at scale; 100% claim payment rate is on a small initial sample.
- International trade/tariff uncertainties cited as headwind to OTC and distributor sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354133 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | DEF 14A | $1.76 | awaiting T+20 | — | $1.72 (−2.27%) |
Oct 15, 2026 11d ago | 8-K | $1.85 | awaiting T+20 | — | $1.72 (−7.03%) |
Oct 8, 2026 19d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.72 (−8.99%) |
Oct 8, 2026 19d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.72 (−8.99%) |
Sep 25, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.72 (+25.86%) |
Sep 24, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.72 (+25.86%) |
Sep 1, 2026 7w ago | Press Release | $2.09 $2.26 | ▲ +8.13% | ▲ +7.82% | $1.72 (−17.70%) |
Aug 27, 2026 8w ago | Insider Cluster | $2.14 $2.39 | ▲ +11.68% | ▲ +12.16% | $1.72 (−19.63%) |
Aug 26, 2026 8w ago | 8-K | $2.10 $2.40 | ▼ −14.29% | ▼ −14.39% | $1.72 (+18.10%) |
Jun 4, 2026 20w ago | 8-K | $2.12 $1.73 | ▼ −18.40% | ▼ −20.26% | $1.72 (−18.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers